Market Cap 158.48M
Revenue (ttm) 0.00
Net Income (ttm) -51.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 5.10
Volume 81,000
Avg Vol 107,262
Day's Range N/A - N/A
Shares Out 16.34M
Stochastic %K 34%
Beta 1.19
Analysts Strong Sell
Price Target $15.50

Company Profile

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node–targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node–targeted AMP peptide vaccine in preclinical studies for the treatment of mutant b-raf murine sarcoma...

Industry: Biotechnology
Sector: Healthcare
Phone: (857) 209-0050
Website: elicio.com
Address:
451 D Street, 5th Floor Suite 501, Boston, United States
Woooehoo
Woooehoo Oct. 22 at 11:03 AM
$ELTX I see it as unlikely this doesn’t go decently higher or decently lower with data in q4
3 · Reply
DrevanTheStillblade
DrevanTheStillblade Oct. 19 at 8:33 PM
Don’t sleep on VRME while many tech names trade on hype, this one trades on value + technical setup. Golden cross brewing on the daily, 10‑day action above $1 reflecting compliance improvement, and it’s still under the radar. This combination rarely stays hidden for long. $PSNY $ELTX $XELA $SLNO
0 · Reply
justiceforb_85
justiceforb_85 Oct. 12 at 2:22 AM
$ELTX we've received a possible hint that DFS wil be outstanding in the P2. Median mKRAS-specific T cell response ~44 when prior studies showed clinical efficacy around 9.17. I am very hopeful this translates into clinically meaningful outcomes. https://elicio.com/press_releases/elicio-therapeutics-reports-eli-002-7p-achieved-robust-mkras-specific-t-cell-responses-in-99-of-evaluable-patients-in-ongoing-phase-2-amplify-7p-trial/
0 · Reply
COYIinnewyork
COYIinnewyork Oct. 9 at 6:43 PM
$ELTX I've only been holding a few thousand shares. I'm holding it amongst others, but I've always wondered with this in particular why MRK, BMY, or PFE don't swoop it up to fill their immuno-oncology pipelines. Do you think they are waiting on the specific data like everyone else? Would ELTX sell to one of them on positive data or would partnering be the way to go?
1 · Reply
outlawinvestor1
outlawinvestor1 Oct. 3 at 4:38 PM
$ERAS #KRAS landscape. SA doesn't update mc/ev in real-time - ERAS mc is now ~$720 million, cash is ~$350 million. @Night_Owl_Biotech $RVMD $VSTM $ELTX $ARVN
0 · Reply
justiceforb_85
justiceforb_85 Sep. 29 at 7:12 PM
$ELTX this is excellent news and means more patients would potentially qualify for ELI-002 7P. https://elicio.com/press_releases/elicio-therapeutics-announces-investigator-initiated-phase-1-trial-to-be-conducted-by-memorial-sloan-kettering-cancer-center-and-funded-by-the-lustgarten-foundation-for-neoadjuvant-eli-002-7p-in-pancr/
0 · Reply
LawrenceLay406
LawrenceLay406 Sep. 21 at 10:52 AM
$ELTX Biotech with novel approach. Pre-revenue volatility. Chart shows high risk/reward. Avoid.
0 · Reply
Woooehoo
Woooehoo Sep. 18 at 12:17 PM
$ELTX if p2 is anything like p1 should show solid efficacy of T cell response is even better
2 · Reply
justiceforb_85
justiceforb_85 Sep. 17 at 4:59 PM
$ELTX looking forward to P2 data later this year. Wonder if they would qualify for accelerated approval pending P3 completion.
1 · Reply
PMMstocks
PMMstocks Sep. 17 at 1:52 PM
$ELTX https://elicio.com/press_releases/elicio-therapeutics-reports-eli-002-7p-achieved-robust-mkras-specific-t-cell-responses-in-99-of-evaluable-patients-in-ongoing-phase-2-amplify-7p-trial/
0 · Reply
Latest News on ELTX
Elicio Therapeutics Reports Inducement Grants

Sep 18, 2025, 8:00 AM EDT - 5 weeks ago

Elicio Therapeutics Reports Inducement Grants


Elicio Therapeutics Secures $10 Million in Financing

Jun 4, 2025, 8:00 AM EDT - 5 months ago

Elicio Therapeutics Secures $10 Million in Financing


Elicio Therapeutics Announces Proposed Public Offering

Jun 27, 2024, 4:05 PM EDT - 1 year ago

Elicio Therapeutics Announces Proposed Public Offering


Woooehoo
Woooehoo Oct. 22 at 11:03 AM
$ELTX I see it as unlikely this doesn’t go decently higher or decently lower with data in q4
3 · Reply
DrevanTheStillblade
DrevanTheStillblade Oct. 19 at 8:33 PM
Don’t sleep on VRME while many tech names trade on hype, this one trades on value + technical setup. Golden cross brewing on the daily, 10‑day action above $1 reflecting compliance improvement, and it’s still under the radar. This combination rarely stays hidden for long. $PSNY $ELTX $XELA $SLNO
0 · Reply
justiceforb_85
justiceforb_85 Oct. 12 at 2:22 AM
$ELTX we've received a possible hint that DFS wil be outstanding in the P2. Median mKRAS-specific T cell response ~44 when prior studies showed clinical efficacy around 9.17. I am very hopeful this translates into clinically meaningful outcomes. https://elicio.com/press_releases/elicio-therapeutics-reports-eli-002-7p-achieved-robust-mkras-specific-t-cell-responses-in-99-of-evaluable-patients-in-ongoing-phase-2-amplify-7p-trial/
0 · Reply
COYIinnewyork
COYIinnewyork Oct. 9 at 6:43 PM
$ELTX I've only been holding a few thousand shares. I'm holding it amongst others, but I've always wondered with this in particular why MRK, BMY, or PFE don't swoop it up to fill their immuno-oncology pipelines. Do you think they are waiting on the specific data like everyone else? Would ELTX sell to one of them on positive data or would partnering be the way to go?
1 · Reply
outlawinvestor1
outlawinvestor1 Oct. 3 at 4:38 PM
$ERAS #KRAS landscape. SA doesn't update mc/ev in real-time - ERAS mc is now ~$720 million, cash is ~$350 million. @Night_Owl_Biotech $RVMD $VSTM $ELTX $ARVN
0 · Reply
justiceforb_85
justiceforb_85 Sep. 29 at 7:12 PM
$ELTX this is excellent news and means more patients would potentially qualify for ELI-002 7P. https://elicio.com/press_releases/elicio-therapeutics-announces-investigator-initiated-phase-1-trial-to-be-conducted-by-memorial-sloan-kettering-cancer-center-and-funded-by-the-lustgarten-foundation-for-neoadjuvant-eli-002-7p-in-pancr/
0 · Reply
LawrenceLay406
LawrenceLay406 Sep. 21 at 10:52 AM
$ELTX Biotech with novel approach. Pre-revenue volatility. Chart shows high risk/reward. Avoid.
0 · Reply
Woooehoo
Woooehoo Sep. 18 at 12:17 PM
$ELTX if p2 is anything like p1 should show solid efficacy of T cell response is even better
2 · Reply
justiceforb_85
justiceforb_85 Sep. 17 at 4:59 PM
$ELTX looking forward to P2 data later this year. Wonder if they would qualify for accelerated approval pending P3 completion.
1 · Reply
PMMstocks
PMMstocks Sep. 17 at 1:52 PM
$ELTX https://elicio.com/press_releases/elicio-therapeutics-reports-eli-002-7p-achieved-robust-mkras-specific-t-cell-responses-in-99-of-evaluable-patients-in-ongoing-phase-2-amplify-7p-trial/
0 · Reply
topstockalerts
topstockalerts Sep. 17 at 1:31 PM
$ELTX keep an eye for today..
0 · Reply
humdime
humdime Sep. 17 at 1:09 PM
$ELTX Not just replicating Phase 1 but actually improving it. We’ll see the real efficacy, but comparing this data with Phase 1, it looks like a game changer at bargain price
0 · Reply
truehealthvalue
truehealthvalue Sep. 17 at 12:55 PM
$ELTX may I be wrong, but today news are best-in-class results. Better than MRNA with 100x lower valuation
0 · Reply
outlawinvestor1
outlawinvestor1 Sep. 15 at 1:51 PM
$RNXT just the beginning for renovo and a few others in pancan. $RVMD $VSTM $ELTX $CADL
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 5 at 10:22 PM
$ELTX Brilliant piece that captures ELTX's situation perfectly. So if you want to update your understanding of ELTX or get to know ELTX better, this is essential reading. https://beyondspx.com/quote/ELTX/elicio-therapeutics-amp-technology-s-promise-meets-a-critical-funding-juncture-nasdaq-eltx#analysis
1 · Reply
Pokerguden
Pokerguden Aug. 26 at 1:56 PM
$ELTX Seems like next catalysts are a few months away. 10-20% drop from here before next spike. Hoping for sub 9 entry 1 month from now.
0 · Reply
justiceforb_85
justiceforb_85 Aug. 25 at 6:14 PM
$ELTX added more. Look forward to data in Q4.
0 · Reply
GannAnalysisCapital
GannAnalysisCapital Aug. 23 at 1:22 PM
$ELTX Elicio Therapeutics Inc is a clinical stage oncology company with vaccine platform
0 · Reply
justiceforb_85
justiceforb_85 Aug. 19 at 7:25 PM
$ELTX holding strong. Impressed there hasn't been an offering (though wouldn't blame the company if they did).
4 · Reply
Woooehoo
Woooehoo Aug. 19 at 12:39 PM
$ELTX needs one big randomized DFS win in Q4 and then there is no reason this isn’t at least a $B market cap
0 · Reply
RealtorNewYork
RealtorNewYork Aug. 19 at 12:26 AM
$ELTX The study was sponsored and funded by Elicio Therapeutics, the Massachusetts company that developed the vaccine. Mutations in the KRAS gene are responsible for half of colorectal cancers and more than 90% of pancreatic cancers. The vaccine, which targets those mutations, was given via a series of injections to activate an immune response in the lymph nodes. A majority (21 out of 25) of the patients generated "KRAS-specific T cells," which indicates a stronger immune response. The ones with higher T-cell responses showed a longer relapse-free survival compared to those with lower responses, the researchers found. For three colorectal cancer patients and three pancreatic cancer patients, the vaccine appeared to remove all disease biomarkers.
0 · Reply
RealtorNewYork
RealtorNewYork Aug. 19 at 12:19 AM
$ELTX BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the publication of follow-up data from the Phase 1 AMPLIFY-201 study evaluating ELI-002 in the peer-reviewed scientific journal, Nature Medicine. The article, entitled, “Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: Phase 1 AMPLIFY-201 trial final results,” highlights that with extended follow-up, more than two-thirds of participants (17 of 25) whose T cell responses exceeded the antitumor efficacy threshold experienced a significantly reduced risk for relapse or death.
0 · Reply